SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?
6 references·2 citing·31 second hop
Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric? (2010)Comparison of Anticancer Drug Coverage De…Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Limits on Medicare's Ability …Health Technology Assessment in Health-Care Decisions in the United States (2009)Health Technology Assessment …Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’ (2006)Coverage Options For Promisin…Medicare and Cost-Effectiveness Analysis (2005)Medicare and Cost-Effectivene…Why don't Americans use cost-effectiveness analysis? (2004)Why don't Americans use cost-…What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)What Is the Price of Life and…Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US (2014)Cancer economics, policy and …Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial (2011)Cost-effectiveness analysis o…Costs, effects and C/E‐ratios alongside a clinical trial (1994)Cost-Effectiveness in Health and Medicine (1996)The Cochrane Library (2005)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)The Role of Cost-effectiveness Analysis in Health and Medicine (1996)The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine (1996)Biologic drugs for rheumatoid arthritis in the medicare program: A cost‐effectiveness analysis (2008)Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists (2010)When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in Oncology (2010)Protected Values and Omission Bias (1999)Willingness to Pay for a Quality-adjusted Life Year (2000)Interpreting the Results of Cost-Effectiveness Studies (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors (2018)Delivering affordable cancer care in high-income countries (2011)Economic burden of cancer across the European Union: a population-based cost analysis (2013)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)The price of innovation: new estimates of drug development costs (2003)Cancer Drugs in the United States: Justum Pretium—The Just Price (2013)Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity (2014)Five Years of Cancer Drug Approvals (2015)Assessing Medical Technologies (1985)Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? (2010)Foundations of Cost-Effectiveness Analysis for Health and Medical Practices (1977)Setting Health Care Priorities in Oregon (1991)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Trends in Cost Effectiveness Analyses in Orthopaedic Surgery (2007)Median-Based Incremental Cost-Effectiveness Ratio (ICER) (2012)Coverage with Evidence Development: An examination of conceptual and policy issues (2007)Funding the Unfundable (2010)Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers (2010)
this work references cited by second hop

References

  • 2003What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation?588 cited
  • 2009Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs391 cited
  • 2005Medicare and Cost-Effectiveness Analysis225 cited
  • 2006Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’210 cited
  • 2004Why don't Americans use cost-effectiveness analysis?110 cited
  • 2009Health Technology Assessment in Health-Care Decisions in the United States93 cited

Cited by

  • 2011Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial77 cited
  • 2014Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US70 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work